Publications hub
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
We’re still confirming the best location for some of our content. Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Non-prescription medicines (10)
- (-) Regulatory compliance (8)
- (-) Alert/Advisory (3)
- Advisory bodies and committees (364)
- Scheduling (national classification system) (157)
- Prescription medicines (36)
- Advertising (25)
- In Vitro Diagnostic medical devices (IVDs) (24)
- Medicine safety (23)
- Therapeutic goods regulation (20)
- Medical devices safety (14)
- Manufacturing (11)
- Safety (11)
- Complementary medicines (9)
- Over the counter (OTC) medicines (8)
- COVID-19 vaccines (7)
- Listed medicines (7)
- Registered complementary medicines (7)
- COVID-19 (6)
- Medicinal cannabis hub (6)
- Assessed listed medicines (5)
- Shortages (4)
- Clinical trials (3)
- Fees and payments (3)
- Legislation (3)
- Compliance and enforcement hub (2)
- Import and export (2)
- Sunscreens (2)
- Artificial Intelligence (AI) (1)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biological medicines (1)
- Breast implant hub (1)
- Cosmetics (1)
- Disinfectants/Sterilants (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Pharmacovigilance (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
20 result(s) found, displaying 1 to 20
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 November 2024
-
PublicationsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
PublicationsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 March 2024
-
PublicationsWe commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.
-
PublicationsThis fact sheet is for healthcare practitioners to help understand the rules surrounding importation of cosmetic injectables.
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 March 2023
-
PublicationsThe TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2021-22
-
TGA laboratory testing reportsIn consultation with the TGA, Edgewell has taken a precautionary approach and commenced a recall of all batches of these three products from the Australian market.
-
PublicationsUpdates to the ICMRA landing page detailing ICMRA's projects and their role during the COVID-19 pandemic.
-
PublicationsThe PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health
-
PublicationsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
PublicationsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
TGA laboratory testing reportsThis testing project was designed to assess compliance with the new Standard
-
TGA laboratory testing reportsTGA Laboratories has released a report detailing testing of alkyl nitrite products
-
PublicationsStatistics from inspections conducted from 1 September 2017 to 31 December 2018
-
PublicationsOTC application placement question and answer tool
-
PublicationsThis Code supersedes the November 1991 edition of the Australian Code of Good Wholesaling Practice for Therapeutic Goods for Human Use.